Business
Why the Immutep (ASX:IMM) share price is up 6% today
The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company’s shares are up 5.97% to 36 cents.
New Phase 2b trial
The Immutep share price is on the move as investors have been rallying up on the positive news.
According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.
HNSCC is an aggressive life-threatening cancer that affects either the…
-
Noosa News22 hours agoExperts share tiny home warning as interest from young people soars
-
Noosa News21 hours agoExpert’s warning as tourists stunned by hundreds of sharks spotted close to shore at Moreton Island, Queensland
-
General18 hours agoConvicted mushroom murderer Erin Patterson outlines her reasons to appeal
-
General7 hours agoSussan Ley’s net zero problem won’t only impact the Coalition